RhumbLine Advisers
ATHE

RhumbLine Advisers’s Alterity Therapeutics ATHE Stock Holding History

RhumbLine Advisers’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.01K Sell
1,970
-157
-7% -$532 ﹤0.01% 3841
2025
Q4 		$6.55K Buy
2,127
+1,241
+140% +$4.74K ﹤0.01% 3907
2025
Q3 		$3.34K Buy
886
+756
+582% +$3.65K ﹤0.01% 3943
2025
Q2 		$533 Hold
130
– – ﹤0.01% 4071
2025
Q1 		$450 Buy
+130
New +$498 ﹤0.01% 4061

Other funds holding ATHE

TLCM
Twin Lakes Capital Management Redwood Shores, California $220M AUM 31.75% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $15.5B AUM 18.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GT
Greenleaf Trust Kalamazoo, Michigan $10.2B AUM 2.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

RhumbLine Advisers's ATHE Position: Q1 2026 in Review

RhumbLine Advisers reduced its Alterity Therapeutics (ATHE) stake by 7.4% in Q1 2026, selling an estimated $532 and leaving 1,970 shares worth $7.01K. The position accounts for ﹤0.01% of the portfolio, ranked #3841.

RhumbLine Advisers first reported a position in ATHE in Q1 2025 and has held it in 5 quarters since. 15 funds tracked by Wall St. Rank hold ATHE as of Q1 2026.

  • RhumbLine Advisers held 1,970 shares of Alterity Therapeutics worth $7.01K as of Q1 2026.
  • RhumbLine Advisers sold 157 Alterity Therapeutics shares in Q1 2026, an estimated $532.
  • Alterity Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3841 holding.
  • RhumbLine Advisers first reported a position in Alterity Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 15 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.